Пандемия COVID-19 и синдром раздраженного кишечника — есть ли связь?

Цель обзора: отразить особенности течения синдрома раздраженного кишечника (СРК) в период пандемии COVID-19.

Основные положения. Отмечено, что COVID-19 может способствовать формированию постинфекционных функциональных желудочно-кишечных заболеваний из-за ряда предрасполагающих факторов. Рецепторы ангиотензинпревращающего фермента-2 (АПФ-2), место связывания вируса SARS-CoV-2 с клетками организма человека, присутствуют в эпителиальных клетках кишечника; вирус был обнаружен в кале примерно у половины пациентов. Желудочно-кишечные симптомы, в том числе диарея, возникают примерно у одной пятой пациентов. Фекальный кальпротектин, маркер воспаления ЖКТ, повышен у пациентов с COVID-19. У пациентов отмечены макроскопические и микроскопические признаки повреждения слизистой оболочки ЖКТ. COVID-19 ассоциирован с изменением кишечной микробиоты. В условиях пандемии COVID-19 у более чем 90 % из опрошенных пациентов с СРК выявлено обострение заболевания с усилением боли и вздутия живота.

Заключение. Ведение пациентов с СРК в условиях пандемии COVID-19 диктует необходимость комплексного подхода. Примером мультитаргетного препарата, оказывающего влияние на различные патогенетические факторы функциональных заболеваний ЖКТ, служит препарат Колофорт®.

1. Munster V.J., Feldmann F., Williamson B.N., van Doremalen N., Perez-Perez L., Schulz J., et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. 2020;585(7824):268–72. DOI: 10.1038/s41586-020-2324-7

2. Hamid S., Mir M. Y., Rohela G.K. Novel coronavirus disease (COVID-19): a pandemic (epidemiology, pathogenesis and potential therapeutics). New Microbes New Infect. 2020;35:100679. DOI: 10.1016/j.nmni.2020.100679

3. D’Amico F., Baumgart D.C., Danese S., Peyrin-Biroulet L. Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management. Clin Gastroenterol Hepatol. 2020;18(8):1663–72. DOI: 10.1016/j. cgh.2020.04.001

4. Ianiro G., Mullish B.H., Kelly C.R., Sokol H., Kassam Z., Ng S.C., et al. Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel. Lancet Gastroenterol Hepatol. 2020;5(5):430–2. DOI: 10.1016/S2468-1253(20)30082-0

5. Takakura W., Pimentel M. Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome — An Update. Front Psychiatry. 2020;11:664. DOI: 10.3389/fpsyt.2020.00664

6. Klem F., Wadhwa A., Prokop L.J., Sundt W.J. Farrugia G., Camilleri M., et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology 2017;152:1042–54. DOI: 10.1053/j.gastro.2016.12.039

7. Ghoshal U.C., Ranjan P. Post-infectious irritable bowel syndrome: the past, the present and the future. J Gastroenterol Hepatol. 2011;26 (Suppl 3):94–101. DOI: 10.1111/j.1440-1746.2011.06643.x

8. Schmulson M., Ghoshal U.C., Barbara G. Managing the inevitable surge of post-COVID-19 functional gastrointestinal disorders. Am J Gastroenterol. 2021;116:4–7. DOI: 10.14309/ajg.0000000000001062

9. Ghoshal U.C., Ghoshal U., Mathur A., Singh R.K., Nath A.K., Garg A., et al. The spectrum of gastrointestinal symptoms in patients with coronavirus disease-19: predictors, relationship with disease severity, and outcome. Clin Transl Gastroenterol. 2020;11:e00259. DOI: 10.14309/ ctg.0000000000000259

10. Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol 2020;94:e00127-20. DOI: 10.1128/JVI.00127-20

11. Wong M.C., Huang J., Lai C., Ng R., Chan F.K., Chan P.K. Detection of SARS-CoV-2 RNA in fecal specimens of patients with confirmed COVID-19: a meta-analysis. J Infect 2020;81:e31–8. DOI: 10.1128/JVI.00127-20

12. Cardinale V., Capurso G., Ianiro G., Gasbarrini A., Arcidiacono P.G., Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: a working hypothesis. Dig Liver Dis. 2020;52:1383–9. DOI: 10.1016/j.dld.2020.09.009

13. Hanning N., Edwinson A.L., Ceuleers H., Peters S.A., De Man J.G., Hassett L.C., et al. Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review. Therap Adv Gastroenterol. 2021;14:1756284821993586. DOI: 10.1177/1756284821993586

14. Gwee K.A., Collins S.M., Read N.W., Rajnakova A., Deng Y., Graham J.C., et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired postinfectious irritable bowel syndrome. Gut. 2003;52(4):523–6. DOI: 10.1136/gut.52.4.523

15. Downs I.A., Aroniadis O.C., Kelly L., Brandt L.J. Postinfection irritable bowel syndrome: the links between gastroenteritis, inflammation, the microbiome, and functional disease. J Clin Gastroenterol. 2017;51:869–77. DOI: 10.1097/MCG.0000000000000924

16. Villani A.C., Lemire M., Thabane M., Belisle A., Geneau G. , Garg A.X., et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology. 2010;138:1502–13. DOI: 10.1053/j.gastro.2009.12.049

17. Tang H.Y., Jiang A.J., Wang X.Y., Wang H., Guan Y.Y., Li F., et al. Uncovering the pathophysiology of irritable bowel syndrome by exploring the gut-brain axis: a narrative review. Ann Transl Med. 2021;9(14):1187. DOI: 10.21037/atm-21-2779

18. Barbara G., Grover M., Bercik P., Corsetti M., Ghoshal U.C., Ohman L., et al. Rome Foundation Working Team report on post-infection irritable bowel syndrome. Gastroenterology 2019;156(1):46–58. DOI: 10.1053/j.gastro.2018.07.011

19. Ghoshal U.C., Shukla R., Ghoshal U., Gwee K.A., Ng S.C., Quigley E.M. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012;2012:151085. DOI: 10.1155/2012/151085

20. Ong J., Young B.E., Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020;69:1144–5. DOI: 10.1136/gutjnl-2020-321051

21. Gu S., Chen Y., Wu Z., Chen Y., Gao H., Lv L., et al. Alterations of the gut microbiota in patients with COVID-19 or H1N1 influenza. Clin Infect Dis. 2020;71(10):2669–78. DOI: 10.1093/cid/ciaa709

22. Rodrigues P.B., Dos Santos Pereira Gomes A.B., Genaro L.M., Pascoal L.B., de Souza A.P., Leal R.F. Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known? Adv Exp Med Biol. 2021;1327:93–106. DOI: 10.1007/978-3-030-71697-4_7

23. Tian Y., Sun K.Y., Meng T.Q., Guo S.M., Li G.M., Xiong G.L., et al. Gut Microbiota May Not Be Fully Restored in Recovered COVID-19 Patients After 3-Month Recovery. Front Nutr. 2021;8:638825. DOI: 10.3389/fnut.2021.638825

24. Gaibani P., D’Amico F., Bartoletti M., Lombardo D., Rampelli S., Fornaro G., et al. The Gut Microbiota of Critically Ill Patients With COVID-19. Front Cell Infect Microbiol. 2021;11:670424. DOI: 10.3389/fcimb.2021.670424

25. Sokol H., Contreras V., Maisonnasse P., Desmons A., Delache B., Sectio V., et al. SARS-CoV-2 infection in nonhuman primates alters the composition and functional activity of the gut microbiota. Gut Microbes. 2021;13(1):1–19. DOI: 10.1080/19490976.2021.1893113

26. Chen J., Hall S., Vitetta L. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol. 2021;31(5):1–13. DOI: 10.1002/rmv.2211

27. Zhou Y., Zhang J., Zhang D. Ma V.L., Wang X., et al. Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge. Microbiol. 2021;59(10):941–8. DOI: 10.1007/s12275-021-1206-5

28. Yamamoto S., Saito M., Tamura A., Prawisuda D, Mizutani T., Yotsuyanagi H. The human microbiome and COVID-19: A systematic review. PLoS One. 2021;16(6):e0253293. DOI: 10.1371/journal.pone.0253293

29. Zuo T., Zhang F., Lui G.C., Yeoh Y.K., Li A.Y.L., Zhan H., et al. Alterations in gut microbiota of patients with COVID-19 during time of hospitalization. Gastroenterology 2020;159:944–55.e8. DOI: 10.1053/j.gastro.2020.05.048

30. Cardinale V., Capurso G., Ianiro G., Gasbarrin A., Arcidiacono P.G., Alvaro D. Intestinal permeability changes with bacterial translocation as key events modulating systemic host immune response to SARS-CoV-2: A working hypothesis. Dig Liver Dis. 2020;52(12):1383–9. DOI: 10.1016/j.dld.2020.09.009

31. Effenberger M., Grabherr F., Mayr L., Schwaerzler J., Nairz M., Seifert M., et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020;69:1543–4. DOI: 10.1136/gutjnl-2020-321388

32. Quek S.X.Z., Loo E.X.L, Demutska A, Chua C.E., Kew G.S., Wong S., et al. Impact of the coronavirus disease 2019 pandemic on irritable bowel syndrome. J Gastroenterol Hepatol. 2021;36(8):2187–97. DOI: 10.1111/jgh.15466

33. Nam Y., Kwon S.C., Lee Y.J., Jang E.C., Ahn S.H. Relationship between job stress and functional dyspepsia in display manufacturing sector workers: a cross-sectional study. Ann Occup Environ. Med. 2018;30:62. DOI: 10.1186/s40557-018-0274-4

34. Felstead A., Henseke G. Assessing the growth of remote working and its consequences for effort, well-being and work-life balance. New Technol Work Employ. 2017;32(3):195–212. DOI: 10.1111/ntwe.12097

35. Oshima T., Siah K.T.H., Yoshimoto T., Miura K., Tomita T., Fukui H., et al. Impacts of the COVID-19 pandemic on functional dyspepsia and irritable bowel syndrome: A population-based survey. J Gastroenterol Hepatol. 2021;36(7):1820–7. DOI: 10.1111/jgh.15346

36. Scarmozzino F., Visioli F. Covid-19 and the subsequent lockdown modified dietary habits of almost half the population in an Italian sample. Foods 2020;9(5):675. DOI: 10.3390/foods9050675

37. Hislop T.G., Bajdik C.D., Balneaves L.G., et al. Physical and emotional health effects and social consequences after participation in a low-fat, high-carbohydrate dietary trial for more than 5 years. J Clin Oncol. 2006;24(15):2311–7. DOI: 10.1200/JCO.2005.04.3042

38. Liese A.D., Weis K.E., Pluto D., Smith E., Lawson A. Food store types, availability, and cost of foods in a rural environment. J Am Diet Assoc. 2007;107(11):1916–23. DOI: 10.1016/j.jada.2007.08.012

39. Barrett J.S. Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. Nutr Clin Pract. 2013;28(3):300–6. DOI: 10.1177/0884533613485790

40. Coroiu A., Moran C., Campbell T., Geller A.C. Barriers and facilitators of adherence to social distancing recommendations during COVID-19 among a large international sample of adults. PLoS One. 2020;15:e0239795. DOI: 10.1371/journal.pone.0239795

41. Alzahrani M.A., Alshamrani A.S., Ahmasani I.M., Alahmari F.S., Asiri A.H., Alshehri A.M. Coronavirus disease 2019 pandemic stress and its effects on irritable bowel syndrome patients in Saudi Arabia. Medicine (Baltimore). 2020;99(51):e23711. DOI: 0.1097/MD.0000000000023711

42. Conte L., Toraldo D.M. Targeting the gut-lung microbiota axis by means of a high-fibre diet and probiotics may have anti-inflammatory effects in COVID-19 infection. Ther Adv Respir Dis. 2020;14:1753466620937170. DOI: 10.1177/1753466620937170

43. Mehtab W., Agarwal A., Singh N., Malhotra A., Makharia G.K. All that a physician should know about FODMAPs. Indian J Gastroenterol 2019;38:378–90. DOI: 10.1007/s12664-019-01002-0

44. Ghoshal U.C. Pros and cons while looking through an Asian window on the Rome IV criteria for irritable bowel syndrome: pros. J Neurogastroenterol Motil. 2017;23:334–40. DOI: 10.5056/jnm17020

45. Zhang Q., Yue S., Wang W., Chen Y., Zhao C., Song Y., et al. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19. Am J Chin Med. 2021;49(4):785–803. DOI: 10.1142/S0192415X21500373

46. d’Ettorre G., Ceccarelli G., Marazzato M., Campagna G., Pinacchio C., Alessandri F., et al. Challenges in the management of SARS-CoV2 Infection: The role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front. Med. 2020;7:389. DOI: 10.3389/fmed.2020.00389

47. Ивашкин В.Т., Маев И.В., Шелыгин Ю.А., Баранская Е.К., Белоус С.С., Белоусова Е.А. и др. Диагностика и лечение синдрома раздраженного кишечника (Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(5):74–95. DOI: 10.22416/1382-4376-2021-31-5-74-95

48. Эртузун И.А., Зуева Е.П., Клылова С.Г., Ефимова Л.А., Дугина Ю.Л., Эпштейн О.И. Экспериментальное изучение «Колофорта» — нового препарата для лечения синдрома раздраженного кишечника и других функциональных заболеваний желудочно-кишечного тракта. Вестник Волгоградского государственного медицинского университета. 2012;4(44):25–27.

49. Ivashkin V.T., Poluektova E.A., Glazunov A.B., Putilovskiy M.A., Epstein O.I. Pathogenetic approach to the treatment of functional disorders of the gastrointestinal tract and their intersection: results of the Russian observation retrospective program COMFORT. BMC Gastroenterol. 2019;20(1):2. DOI: 10.1186/s12876-019-1143-5